Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
Innovation moves quickly, but lasting it’s progress depends on the systems, talent, and leadership built to support it. This week, Greater Philadelphia showcased how the region is balancing rapid scientific advancement with the infrastructure needed to sustain long-term growth.
AI is settling into the background as infrastructure, not a novelty. Kymanox’s new KAI Engine pairs every AI-generated output with human review, a practical approach that mirrors the FDA’s growing focus on governance over hype. That same shift toward smarter execution is showing up in development timelines, too, with Dispatch Bio earned Fast Track designation.
But faster science only goes so far without the people to sustain it. NIIMBL’s new $8 million investment in workforce development is a reminder that talent remains one of the industry’s biggest bottlenecks.Across the region, investments like Delaware’s efforts to strengthen its statewide innovation ecosystem highlight how strategic workforce and infrastructure development. That same emphasis on sustainable growth is reflected in leadership changes across the life sciences landscape. Organizations are turning to experienced leaders who can guide companies through their next stages of expansion, including recent moves at J&J and TELA Bio.
Financial
Tracking the capital moving through Greater Philadelphia— funding rounds, M&A activity, and investment trends shaping Philadelphia, Southern New Jersey, and Delaware’s life sciences companies.
Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development
Glucotrack has closed a $5.5 million financing, its first raise since completing a business combination with Lōkahi Therapeutics that left Lōkahi securityholders owning roughly 90% of the combined company. The deal effectively turns Glucotrack’s public listing into a vehicle for Lōkahi’s AI-driven biopharma asset-acquisition strategy, while its original glucose-monitoring technology continues on as a separate subsidiary. Read More >
Grace Therapeutics Announces $10 Million Private Placement
Grace Therapeutics has closed a $10 million private placement to fund a dual-source manufacturing strategy for GTx-104, its injectable brain hemorrhage treatment that received an FDA rejection over manufacturing, not clinical, issues. The company is remediating its existing contract manufacturer while transferring production to a second U.S.-based facility, ensuring it isn’t dependent on a single path back to FDA resubmission. Read More >
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
Wayne, PA-based Teleflex has completed the $1.5 billion sale of its OEM business to private equity firms Montagu and Kohlberg, the largest piece of a broader restructuring that started as a planned corporate spin-off and ended as a straight $2.03 billion combined divestiture. The proceeds go toward paying down debt and share buybacks, leaving Teleflex a narrower company focused on vascular access, interventional, and surgical care. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Johnson & Johnson Names Tom Cavanaugh to Lead Innovative Medicine Business
Johnson & Johnson has named Tom Cavanaugh EVP, Worldwide Chairman, Innovative Medicine, effective September 1, succeeding Jennifer Taubert as she retires after growing the business to more than $60 billion in annual revenue. Cavanaugh, a nine-year J&J veteran who most recently led the company’s largest commercial region across North America, brings prior P&L leadership across oncology and immunology. Read More >
Clinilabs Announces Medical Leadership Appointments
Clinilabs, an Eatontown, NJ-based CNS-focused CRO, has appointed Bob Dagher, M.D., as Chief Medical Officer and Waqar Siddiqui, M.D., as Principal Investigator of its Eatontown Clinical Research Unit. Dagher brings over 20 years of CMO experience across neuropsychiatry and rare CNS disease programs, while Siddiqui adds 25 years of clinical psychiatry and CNS trial leadership to strengthen the company’s sponsor-facing research capabilities. Read More >
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
Malvern-based TELA Bio has appointed Heather Getz as CEO, succeeding co-founder Antony Koblish as the soft-tissue reconstruction company enters its next phase of commercial growth. Getz brings a track record of financial and operational leadership from Butterfly Network and BioTelemetry, where she helped grow the company’s market cap from $50 million to $2.8 billion before its acquisition by Philips. Read More >
Angela Fernandez-Iglesias, Ph.D., Joins Rockland Immunochemicals as Product Manager
Angela Fernandez-Iglesias, Ph.D., also BioBuzz’s Philadelphia Ambassador, has joined Pottstown-based Rockland Immunochemicals as Product Manager, bringing a research background in gene therapy and growth plate biology together with commercial strategy experience to lead product initiatives across the company’s antibody and reagent portfolio. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Philadelphia, New Jersey, and Delaware life sciences and biotech employers.
NIIMBL Announces $8 Million for Technology & Workforce Development Projects- Apply Now
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is offering a combined $8 million with applications opened August 3rd for Project Call 10.1, with the workforce track funding projects to improve cross-regional workforce development, advanced therapeutic modalities training, and building a digitally fluent biomanufacturing workforce. Apply Now >
Who’s hiring?!
Top Employer
A global healthcare leader spanning pharmaceuticals, medical technologies, and innovative medicines, J&J is advancing breakthroughs across oncology, immunology, neuroscience, cardiovascular disease, and cell therapy. From early-stage research to commercialization, the company combines scientific innovation with global scale to deliver solutions that improve and extend lives.
With a major R&D and commercial footprint across the Greater Philadelphia region, they continue to strengthen one of the nation’s leading life sciences ecosystems by bringing together scientists, clinicians, engineers, data experts, and commercial leaders dedicated to transforming healthcare and delivering life-changing therapies to patients worldwide.
They are currently hiring across 40+ roles in the Greater Philadelphia region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- Jazz Pharmaceuticals (Philadelphia, PA) is hiring a Director, Clinical Quality Assurance | Apply Now >
- Cabaletta Bio (Philadelphia, PA) is hiring a Scientist – Cellular Immunology Preclinical | Apply Now >
- Madrigal (Conshohocken, PA) is hiring a Senior Director, Clinical Supply Release | Apply Now >
- Globus Medical Inc. (Eagleville, PA) is hiring a Assembly Technician, 1st Shift | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across Greater Philadelphia.
Kymanox Launches AI-Enabled Quality and Regulatory Capabilities for Life Sciences Organizations
Kymanox, with a King of Prussia, PA presence, has launched its Kymanox Artificial Intelligence (KAI) Engine, applying AI to QMS development, batch release report review, and human factors study optimization for pharma, biotech, and medical device clients, with every output verified by human experts. The launch positions responsible, expert-supervised AI as a differentiator as clients and regulators like the FDA increasingly expect governed, not just deployed, AI in regulated work. Read More >
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
IMUNON’s pivotal Phase 3 trial for its ovarian cancer immunotherapy IMNN-001 is signing up patients well ahead of both the company’s own projections and typical industry pace, moving from protocol approval to first patient dosed in about a third of the usual time. The strong enrollment momentum is a good sign for a small biotech running a costly, multi-year trial in one of the deadlier cancers affecting women. Read More >
A Philadelphia-Area Biotech Just Got the Green Light for a Genomics-Guided Endometriosis Trial in the UAE
West Conshohocken-based Medicus Pharma has received authorization to launch a Phase 2a trial in the UAE testing its drug Teverelix for endometriosis, pairing the study with genomic analysis from day one to help predict which patients respond best to which dose. The genomics-driven approach aims to tackle the wildly inconsistent patient response that’s long plagued endometriosis treatment. Read More >
BriaCell Receives FDA Clearance to Initiate Bria-PROS+(TM) Clinical Study in Prostate Cancer
BriaCell Therapeutics has received FDA clearance to begin a Phase 1/2a trial of Bria-PROS+, extending its personalized cancer immunotherapy platform, already in a pivotal Phase 3 breast cancer trial, into a second cancer indication. The prostate cancer program builds on the same validated cell-based technology and previously secured a $2 million non-dilutive grant from the National Cancer Institute. Read More >
Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers
Philadelphia-based Dispatch Bio has dosed its first patient in a Phase 1 trial of DISP-10, combining a tumor-specific virus with Bristol Myers Squibb’s BCMA-directed CAR T therapy to target advanced GI cancers, and the FDA has granted it Fast Track designation. The approach aims to overcome long-standing barriers to immunotherapy in solid tumors. Read More >
Ecosystem
The partnerships, programs, and policy moves building Greater Philadelphia’s life sciences infrastructure — and the organizations driving it forward.
Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania
Altasciences has expanded its R&D lab at its Harleysville facility, integrating formulation development and analytical testing into a single environment to bring CDMO capabilities to clients earlier in the drug development journey. The move reflects the company’s broader strategy of positioning itself as the industry’s most connected early-phase drug development partner, betting that fewer handoffs, not more services, is what speeds a therapy to patients. Read More >
Governor Meyer Launches Innovate Delaware to Build Out Delaware’s Innovation Infrastructure
Delaware has launched Innovate Delaware, a new statewide initiative backed by funding that connects entrepreneurs, researchers, and companies to the state’s scattered innovation resources, targeting biopharma manufacturing and advanced materials among its priority sectors. The push builds on Delaware’s existing strengths, home to NIIMBL, Incyte, and W.L. Gore, and roughly 30% of the country’s biochemists and biophysicists, with its first major initiative being the CMS-funded Delaware Rural Health Challenge. Read More >
Why Analytical Development Is Becoming a Bottleneck and a Competitive Advantage – in Biotherapeutics
Across peptides, oligonucleotides, and antibodies, program speed hinges less on the molecule and more on the analytical method behind it, and the scarce talent who can build and transfer one into GMP quality control. Greater Philadelphia’s dense cluster of drug developers and CDMOs means that talent is a strategic resource companies must deliberately source and retain, a theme central to the Biopharma Analytical Innovation Summit on September 16 in Malvern. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in PHL biotech and life sciences this week.
Pharmaceutical Facility Planning: Designing Flexible, Sustainable Manufacturing Facilities
Greater Philadelphia-based Genesis AEC’s Michael Marone, AIA, and Christopher Ham, PE, break down how early-stage strategic planning reduces risk and accelerates schedules for pharmaceutical manufacturing projects, from greenfield site selection to sustainable HVAC and cleanroom optimization. Presented at the American Pharmaceutical Manufacturing & Outsourcing Summit (APOS), the session draws on Genesis AEC’s experience delivering over 10,000 complex life sciences projects. Watch Now >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across Greater Philadelphia’s life sciences ecosystem that you don’t want to miss.
Premier Networking Event Series for the Life Sciences
Tuesday, August 11 • 6 – 9 PM EDT • Glen Mills, PA
Hosted by PA Bio Pharma Networking Group | Register Now >
Transparency and HCP Engagement Conference 2026
Tuesday – Thursday, August 11-13 • 4:30 – 6:30 PM EDT • Philadelphia, PA
Hosted by Informa Connect Life Sciences | Register Now >
Life Sciences on the Lawn
Wednesday, August 12 • 4:30 – 6:30 PM EDT • Pittsburgh, PA
Hosted by Life Sciences PA | Register Now >
Did we miss something!? Drop us a line →
Stay connected to BioHealth Capital Region life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the BioHealth Capital Region Roundup every Friday.
The week’s most important life sciences news from BioHealth Capital Region— delivered to your inbox.
